RP 59227

platelet activating factor antagonist

Also Known As:

N-(3-benzoylphenyl)-3-(3-pyridyl)-1H,3H-pyrrolo(1,2-c)-thiazolo-7-carboxamide; RP-59227; 1H,3H-Pyrrolo(1,2-c)thiazole-7-carboxamide, N-(3-(phenylmethyl)phenyl)-3-(3-pyridinyl)-, (+)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - RP 59227: 2
  - Pyridines: 88
    - RP 59227: 2
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - RP 59227: 2

Related Diseases

1.	Vascular System Injuries 04/01/1992 - "Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection."
2.	Myocardial Ischemia (Ischemic Heart Diseases) 10/01/1998 - "Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function."
3.	Reperfusion Injury 10/01/1998 - "Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function."
4.	Ventricular Fibrillation 10/01/1998 - "In contrast, the number of dogs which developed ventricular fibrillation during occlusion and reperfusion was significantly less in RP 59227-treated dogs (8 of 11 in the control group vs. 3 of 12 in the RP 59227-treated group, p < 0.05). "
5.	Myocardial Infarction 10/01/1998 - "Myocardial infarct size expressed as a percent of the area at risk (control, 39.0 +/- 5.0; RP 59227, 24.8 +/- 3.4%) or as a percent of the left ventricle (control, 15.3 +/- 1.9; RP 59227, 9.0 +/- 1.3%) was significantly smaller in the RP 59227-treated group. " 10/01/1998 - "Taken together, these data demonstrate that RP 59227 effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs, and support the concept that PAF plays an important role in the pathogenesis of acute myocardial infarction." 10/01/1998 - "The effect of the platelet activating factor antagonist RP 59227 (Tulopafant) on myocardial infarct size was compared to that of a vehicle-treated control group in barbital-anesthetized dogs subjected to 90 min of left circumflex coronary artery occlusion and 5 h of reperfusion. "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Barbital (Barbitone)